Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Here's a development that aims to keep your blood pressure in check. Literally!
The company is excluding data from the affected sites to maintain the study's integrity
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Subscribe To Our Newsletter & Stay Updated